Strategic Partnerships Perceptive’s active collaborations with oncology and radiopharmaceutical players (Certis Oncology, MH3D, α-Sight) indicate a strong cross-sell opportunity for imaging biomarkers, RTMS, analytics, and isotope imaging services to expand the portfolio of pharma partners.

Expansion & Capacity Recent facility and capability expansions in Needham Massachusetts and in vitro lab capabilities present capacity to take on larger preclinical oncology programs and expanded imaging studies for new clients seeking scalable outsourcing.

New Service Offerings The launch of Clinical Intelligence Consultancy Service and strategic alliances around forecasting and supply technology signals demand for consulting and operational optimization, creating upsell potential to customers needing end-to-end eClinical and RTSM enhancements.

Portfolio Synergy Integrated offerings spanning imaging biomarkers, core lab services, RTSM, analytics, and software position Perceptive to consolidate vendors for biotech and pharma customers seeking a unified R&D partner, facilitating cross-sell to existing and prospective clients.

Global Growth Signals Recent international collaboration and expansion activity, including Atley asset integration and global clinical intelligence initiatives, suggest opportunities to win new accounts in Europe and North America by emphasizing accelerated timelines and expanded isotope imaging and radiopharmaceutical capabilities.